| Literature DB >> 18241674 |
Su-Ryun Kim1, Yun-Hee Bae, Soo-Kyung Bae, Kyu-Sil Choi, Kwon-Ha Yoon, Tae Hyeon Koo, Hye-Ock Jang, Il Yun, Kyu-Won Kim, Young-Guen Kwon, Mi-Ae Yoo, Moon-Kyoung Bae.
Abstract
Visfatin has recently been identified as a novel visceral adipokine which may be involved in obesity-related vascular disorders. However, it is not known whether visfatin directly contributes to endothelial dysfunction. Here, we investigated the effect of visfatin on vascular inflammation, a key step in a variety of vascular diseases. Visfatin induced leukocyte adhesion to endothelial cells and the aortic endothelium by induction of the cell adhesion molecules, ICAM-1 and VCAM-1. Promoter analysis revealed that visfatin-mediated induction of CAMs is mainly regulated by nuclear factor-kappaB (NF-kappaB). Visfatin stimulated IkappaBalpha phosphorylation, nuclear translocation of the p65 subunit of NF-kappaB, and NF-kappaB DNA binding activity in HMECs. Furthermore, visfatin increased ROS generation, and visfatin-induced CAMs expression and NF-kappaB activation were abrogated in the presence of the direct scavenger of ROS. Taken together, our results demonstrate that visfatin is a vascular inflammatory molecule that increases expression of the inflammatory CAMs, ICAM-1 and VCAM-1, through ROS-dependent NF-kappaB activation in endothelial cells.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18241674 DOI: 10.1016/j.bbamcr.2008.01.004
Source DB: PubMed Journal: Biochim Biophys Acta ISSN: 0006-3002